about
Postmarketing surveillance of enalapril. I: Results of prescription-event monitoringThe aging male population and medical care for benign prostatic hyperplasia in CanadaNew drug approval times and 'therapeutic potential' in Canada, Australia, Sweden and the United States during the period 1992 to 1998.Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.The aging Canadian population and hospitalizations for acute myocardial infarction: projection to 2020.Rosiglitazone use and associated adverse event rates in Canada between 2004 and 2010.Issues in the approval of, access to, and post-marketing follow-up of new drugs in Canada: a personal viewpoint.Erythromycin estolate and jaundice."Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement.Need for an improved submission process for listing drugs for reimbursement in Canadian provinces.Drug safety: withdrawn medications are only part of the pictureAssessing prescription medications for priority regulatory review.Respiratory infection and otitis media visits in relation to pneumococcal conjugate vaccine use in SaskatchewanReview of the quality of observational studies of the association between rosiglitazone and acute myocardial infarction.Reliability of the recording of hysterectomy in the Saskatchewan health care system.Health Canada's use of priority review status for drugs for unmet needs.Commentary: Canadian Association for Population Therapeutics: the past, present and future - a personal viewpoint and a call to action.Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost.Use of personal records for research purposes. Identification numbers help maintain confidentiality.A national drug agency.Impact of preexisting health conditions on the outcome of an adverse drug reaction alerting program: gastrointestinal disorders before piroxicam and sulindac therapy.Cutting costs by targeting prescribing practices.Prescription-event monitoring of 10,895 patients treated with alprazolam.Canada's Adverse Drug Reaction Reporting System: A Failing Grade.Hospitalizations for aplastic anemia and agranulocytosis in Saskatchewan: incidence and associations with antecedent prescription drug use.Drug approval times.Promoting adherence to medicines: possible lessons for Canada?Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles?25 years of pharmacoepidemiologic innovation: the Saskatchewan health administrative databases.What Does the New Ontario Pharmacare Plan offer Children and Young Adults with Rare Disorders?Sedative-hypnotic drug use in Canada.Importation of drugs into the United States from Canada.Drug Points: Angio-oedema and urticaria associated with enalapril.Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventionsSerum markers for primary and recurrent breast cancer: BCM-EIA, CAM 26 and CAM 29Plus ça change, plus c'est la même choseAdjuvant chemotherapy in head and neck cancerPrescription-event monitoring: methodology and recent progressComputerisation of urothelial carcinoma records: 16 years' experience with the TNM systemPrescription-Event Monitoring. Recent experience with 5 NSAIDs
P50
Q28359865-EE6956E8-1E52-4703-AA7F-9D2D4FF73816Q33754025-ACDDF56E-4CA3-42B4-B072-5B377B5CB608Q34013603-FAAF39AF-50E0-407D-938F-0D87568BE786Q34034347-833F60AA-4ED3-49B4-A410-80701C5B1902Q34218217-223F1E34-F9C5-4991-8636-A2BAE18D2C8AQ34623567-8CF8E008-D4C0-4482-807F-E4539A709C44Q34759698-757ED60A-179A-41CA-8FD7-7DB4DCFBEF8CQ34993443-757DF023-6E18-4CB4-9E23-875AF7E57BDBQ35007865-6B9E605C-3E53-4368-AE90-B8D91BCD53A6Q35623927-3987B001-DC69-4637-BC01-60FCA24AA86BQ35922956-E4A29E8D-3C36-4CED-AEBE-2C899F42F944Q36128964-04BC7D7B-FE1F-49A4-A78D-90ED733942B3Q37525620-47DB099B-362E-479B-9F4B-F8AF933B0FE4Q38217300-348B0C86-ED47-4890-B0C9-584C4B9102DCQ38506538-C1F1AB7C-E3F2-4C34-8147-6D336D73F20DQ38564042-4D876F43-E515-4B84-B27C-9254E57B1F48Q39800065-3CEE6155-9FE2-4BD5-A025-F6305D9C8C73Q42314647-32AA0494-2E90-4C98-BF87-78B142D8167CQ42815078-69C92A3F-AA16-43D2-BDBB-109D64947577Q42859855-E2317A16-5262-4A55-9F26-50101DB1D418Q43546350-74945EEB-55D1-46C6-ADB8-F4CED8756625Q43559690-012BFACD-CA20-44B5-8EE5-FB25BBB8960AQ43677656-A9587B13-96E0-4343-BAC1-43F6EA597267Q43758870-A0A2D2B2-C986-4A91-80E9-909FC322E824Q44331156-86BB29B1-0619-4B61-82D3-98506EFD7A93Q46912590-6FDA98E8-85DE-45D1-AB37-A561AB9A2514Q47142735-A4522D3E-0F84-4ACF-8284-2D2191BAE624Q47169342-F0F03E09-7AB7-44FF-9A44-A5EADB77E1CAQ48718503-F6AFF771-242C-43A0-A404-47FC52DE438AQ50061265-DFE1112A-9317-4243-94A0-E3F78986BDBBQ53401319-AA9743C0-2533-4683-80EC-BADA928A2034Q55187641-1B578E54-A833-4E9E-91F8-326AAAE19DA5Q55467251-451669E9-F5EC-43D8-9CFA-656DB627DC12Q58974605-55EAE438-CEF2-4791-90C1-D0B90648F3C5Q67562859-E0D76C19-69C8-44A2-82B7-3879E1600623Q67810610-A8BF1DEC-0447-44A1-9657-B7A964CD1D0BQ68417268-BB581A75-8E22-43DC-BA4E-ABF0979E15E4Q68751721-44E30021-8067-4806-ADB8-AC8F222A8CF1Q68858369-F397C341-9F15-4EEC-8A1D-E4BFF08CC932Q69760837-3CF3BBD8-BAEB-48FA-A955-B634819083DD
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
N S Rawson
@ast
N S Rawson
@en
N S Rawson
@es
N S Rawson
@nl
type
label
N S Rawson
@ast
N S Rawson
@en
N S Rawson
@es
N S Rawson
@nl
prefLabel
N S Rawson
@ast
N S Rawson
@en
N S Rawson
@es
N S Rawson
@nl
P31
P496
0000-0001-6843-4890